Get started
MERCK & CO. INC.MERCK & CO. INC.MERCK & CO. INC.

MERCK & CO. INC.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

MRK trade ideas

MRK bounce up from bottom of rangeMRK has been in a range since end of Dec'18 until now. Last week's bar was a doji at the bottom of the range. The Daily chart is showing me an inverted H&S with a potentially weak right shoulder i.e. buying pressure is strong! Target profit 1 is a near resistance as well as 50MA i.e. $77 area. Target profit 2 is the top of the range at $85 area. A little ambitious and loner term though. Disclaimer: I'm not giving trading and investing advice. Just sharing my chart observations. If you have any symbol that you'd like me to analyze, feel free to drop me a comment. Thanks!
NYSE:MRKLong
by leslieyimsm
2
After six-week slide, I am buying MerckMerck is one of my favorite pharmaceutical companies. As far as I can tell, it a genuinely ethical and well-managed company with an above-average ESG rating. Merck has executed pretty consistently, with an average of 2% annual sales growth, 2.5% annual dividend growth, 3% annual earnings growth, and 4% annual free cash flow growth over the past several years. Merck's valuation is quite attractive for a growing, large-cap company. I estimate its forward P/E at 10, forward P/S at 3.4, and PEG under 5. Merck's dividend yield is a juicy 3.76%, and they should have no problem sustaining that given their free cash flow growth. I estimate that Merck has about 16% upside to its median price multiple of the last four years. Market sentiment is quite bullish on Merck. The average analyst summary score is a "buy" at 6.4/10. Merck has about 30% upside to its average analyst price target. Open interest from option traders is in highly bullish territory, with a put-call ratio of 0.56. News lately has been a bit negative for Merck. Today they voluntarily withdrew their drug Keytruda for one of its (many) indications because it didn't meet FDA post-marketing requirements. That's not great, but it won't be devastating to Keytruda revenues. Merck's proposed purchase of Pandion Therapeutics is being investigated for procedural problems, which also isn't great. Plus, the FDA delayed approval of Merck's application for emergency approval for its Covid-19 drug until it produces more data. On the other hand, Merck just submitted a New Drug Application for gefapixant and cut a billion-dollar commercialization deal for Xevinapant. Both those things are positives for the company. Plus, Merck got some positive attention recently due to a large purchase of its stock by Warren Buffett's investment fund. In technical terms, Merck obviously has been in a downtrend, but it's approaching trend line support. I'm looking at buy tomorrow in the $71.50-71.75 range if Merck continues to dip toward support.
NYSE:MRKLong
by ChristopherCarrollSmith
3
MRK LongCompany Profile: Merck & Co., Inc. provides healthcare solutions worldwide. The company offers therapeutic for cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases; neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products. It provides products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat non-small-cell lung, ovarian and breast, esophageal, thyroid, cervical, and brain cancers; and prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases Sector(s): Healthcare Industry: Drug Manufacturers—General Top Institutional Holders: Holder Shares Vanguard Group, Inc. (The) : 209,865,924 Blackrock Inc. : 195,017,904 State Street Corporation : 117,030,114
NYSE:MRKLong
by FNKHTrading
MRK - Tripple bottom bounce - target $82Expect to bounce off from $74. Target 82. ——————————————————— How to read my charts? - Matching color trend lines shows the pattern. Sometimes a chart can have multiple patterns. Each pattern will have matching color trend lines. - The yellow horizontal lines shows support and resistance areas. - Fib lines also shows support and resistance areas. - The dotted white lines shows price projection for breakout or breakdown target.
NYSE:MRK
by PaperBozz
MRK - Merck & Co - WEEKLY Setup - Holding the 200emaI Hate Trading Pharma But... MRK BUYZONE = 74 - 76 Cost Avg Down (CAD) = 72 - 70 1st Target = 79 2nd Target = 82 3rd Target = 86 HODL Target = ATH ______________________________________________________________________________________________________________________ This content is for informational, educational and entertainment purposes only. This is not in any way, shape or form financial or trading advice. Good luck, happy trading and stay chill, 2degreez
NYSE:MRKLong
by UnknownUnicorn7216011
Buy $MRK - NRPicks Feb 07Merck & Co, Inc. provides healthcare solutions worldwide. The company offers treatments for cardiovascular disease, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal infections, fungal infections, insomnia and inflammatory diseases; neuromuscular blocking agents; cholesterol-modifying drugs; and vaginal contraceptive and antibacterial products. Merck is one of the companies that had been selected to develop the vaccine; however, it is still a company with a very high level team of workers and successful products. In terms of its finances, its debt is average relative to industry-competitors, plus it generates enough cash to be able to meet those obligations. Fundamentals: - Growth - 6% estimated growth in net earnings for the next 3 years. - ROE 50.5% VS 17% industry. Technicals: - Price level below SMA 250-200-150 - Williams R% at -78% levels - RSI (36) Oversold -1.5% average upside during the month A correction of 11% was presented from JANUARY 12 to FEBRUARY 5, which stopped at $75.45 support. The correction was presented because the company abandoned the development of the vaccine against COVID, from the support the stock has shown a change of trend. Finally, the technical indicators are favorable and give us a buy signal.
NYSE:MRKLong
by NewroadTrader
1
MRK Technical Analysis 🧙Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, close to 40% of the firm's sales are generated in the United States. If you understand the idea,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
NYSE:MRKLong
by yura_trades
$MRK bear trend will break after (at least) one more swing high.Most of the research is on the page but I'll explain it briefly. The past two clear trends have shown four swing highs before a break (up/down is irrelevant) - the current bearish trend has only seen three swing highs so far. The RSI of the market is low, which usually foreshadows a bullish movement, if you want to argue that the swing high at $84.70 also counts as a swing high in our current bearish trend, then we are just about due for a bullish sprint. I personally don't think we've seen enough swing lows (see previous bear trend) for a momentum break, especially considering that the current trend has the change in CEO & financial report as a catalyst whereas the previous one simply had the financial statement creating momentum.
NYSE:MRKLong
by mjokeym